Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension

Details for Australian Patent Application No. 2005234783 (hide)

Owner Celgene Corporation

Inventors Zeldis, Jerome B.

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2005234783

PCT Pub. Number WO2005/102317

Priority 60/565,174 23.04.04 US

Filing date 21 April 2005

Wipo publication date 3 November 2005

International Classifications

A61K 31/397 (2006.01) - having four-membered rings, e.g. azetidine

A61K 31/40 (2006.01) - having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

Event Publications

16 November 2006 PCT application entered the National Phase

  PCT publication WO2005/102317 Priority application(s): WO2005/102317

29 January 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005234785-Angiostatic agents and methods and compositions for controlling ocular hypertension

2005234782-Methods of using and compositions comprising thalidomide for the treatment and management of pulmonary hypertension